There have been calls for caution when it comes to the use of Pfizer’s respiratory syncytial virus (RSV) vaccine in pregnant women, ahead of an FDA advisory committee meet
GSK has become the first pharma company to get regulatory approval for a vaccine against respiratory syncytial virus (RSV), setting up what looks set to be a highly lucrat
GSK looks set to bring the first vaccine for respiratory syncytial virus (RSV) to market in the EU, after its Arexvy shot was recommended for approval by the EMA’s human m
Moderna’s aspiration to become a player in the seasonal influenza vaccine market has hit a hurdle – likely a delay rather than anything more serious – but its stock has st
Johnson & Johnson has decided to bow out of the market for respiratory syncytial virus (RSV) vaccines, abandoning a late-stage development programme that would have be
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.